2-bromo-5-chlorothiazolo[5,4-d]pyrimidine | 2361568-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 1,3-噻唑并[5,4-d]嘧啶
• 英文名称: 2-bromo-5-chlorothiazolo[5,4-d]pyrimidine
• 英文别名: 2-Bromo-5-chloro-[1,3]thiazolo[5,4-d]pyrimidine
• CAS: 2361568-37-6
• 化学式: C₅HBrClN₃S
• 分子量: 250.506
• InChiKey: TUXIEALZKDGHFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-5-chlorothiazolo[5,4-d]pyrimidine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 15.25h， 生成 5-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine
  参考文献：
  名称：

  WO2020005877A5

  摘要：

  公开号：

  WO2020005877A5
• 作为产物：
  描述：

  (9H-fluoren-9-yl)methyl (5-chlorothiazolo[5,4-d]pyrimidin-2-yl)carbamate 在 哌啶 、 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.5h， 生成 2-bromo-5-chlorothiazolo[5,4-d]pyrimidine
  参考文献：
  名称：

  WO2020005877A5

  摘要：

  公开号：

  WO2020005877A5

文献信息

• [EN] 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 1,3,4,5-TÉTRAHYDRO-2H-PYRIDO[4,3-B]INDOLE POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE TROUBLES ASSOCIÉS À DES AGRÉGATS DE TAU COMME LA MALADIE D'ALZHEIMER
  申请人：AC IMMUNE SA

  公开号：WO2019134978A1

  公开（公告）日：2019-07-11

  The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

  本发明涉及一类新化合物，可用于治疗、缓解或预防与Tau蛋白聚集相关的一组疾病和异常，包括但不限于神经原纤维缠结（NFTs），如阿尔茨海默病（AD）。
• Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection
  作者：Hongwang Zhang、Longhu Zhou、Sarah Amichai、Keivan Zandi、Bryan Cox、Raymond Schinazi、Franck Amblard

  DOI：10.1016/j.bmcl.2019.126639

  日期：2019.10

  Exploration of the chemical space of known influenza polymerase PB2 inhibitor Pimodivir, was performed by our group. We synthesized and identified compounds 16a and 16b, two novel thienopyrimidine derivatives displaying anti-influenza A activity in the single digit nanomolar range in cell culture. Binding of these unique compounds in the influenza polymerase PB2 pocket was also determined using molecular modeling.
• WO2019234243A5
  申请人：——

  公开号：WO2019234243A5

  公开（公告）日：2022-05-09
• HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
  申请人：PTC Therapeutics, Inc.

  公开号：EP3814345A1

  公开（公告）日：2021-05-05
• NOVEL COMPOUNDS FOR DIAGNOSIS
  申请人：AC IMMUNE SA

  公开号：US20210252175A1

  公开（公告）日：2021-08-19

  The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a-synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.